基于血液基因组内型对脓毒症患者进行分类:一项前瞻性队列研究
140基因表达特征可在两个验证队列中可靠分层,BPGM和TAP2可识别Mars1内型。
要点
- 脓毒症患者入院时可基于血液基因表达分为Mars1-4四种分子内型。
- 140基因特征可在验证队列中可靠分层,BPGM和TAP2识别Mars1内型。
核心结论
- 脓毒症患者ICU入院时可分子分类为四种内型(Mars1-4),与28天死亡率相关。
- Mars1内型在发现队列中预后最差,且在各队列中与28天死亡率一致显著相关。
- 检测脓毒症内型可能有助于个体化管理及试验筛选。
研究设计与样本
- 前瞻性观察性队列研究,纳入荷兰两家ICU连续收治的脓毒症患者(发现队列306例、第一验证队列216例)。
- 第二验证队列为英国29家ICU社区获得性肺炎所致脓毒症患者265例。
- 采集入院样本行全血基因组表达谱,采用无监督共识聚类和机器学习分析。
关键数值与推荐
- 140基因表达特征可在第一和第二验证队列中可靠分层四种内型。
- BPGM和TAP2可可靠识别Mars1内型患者。
临床怎么用
- ICU入院时可通过血液基因表达谱对脓毒症患者进行分子分型。
- Mars1内型患者死亡风险较高,可考虑更密切监测或个体化管理。
- 内型检测可能辅助临床试验的患者筛选。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Host responses during sepsis are highly heterogeneous, which hampers the identification of patients at high risk of mortality and their selection for targeted therapies. In this study, we aimed to identify biologically relevant molecular endotypes in patients with sepsis. METHODS: This was a prospective observational cohort study that included consecutive patients admitted for sepsis to two intensive care units (ICUs) in the Netherlands between Jan 1, 2011, and July 20, 2012 (discovery and first validation cohorts) and patients admitted with sepsis due to community-acquired pneumonia to 29 ICUs in the UK (second validation cohort). We generated genome-wide blood gene expression profiles from admission samples and analysed them by unsupervised consensus clustering and machine learning. The primary objective of this study was to establish endotypes for patients with sepsis, and assess the association of these endotypes with clinical traits and survival outcomes. We also established candidate biomarkers for the endotypes to allow identification of patient endotypes in clinical practice. FINDINGS: The discovery cohort had 306 patients, the first validation cohort had 216, and the second validation cohort had 265 patients. Four molecular endotypes for sepsis, designated Mars1-4, were identified in the discovery cohort, and were associated with 28-day mortality (log-rank p=0·022). In the discovery cohort, the worst outcome was found for patients classified as having a Mars1 endotype, and at 28 days, 35 (39%) of 90 people with a Mars1 endotype had died (hazard ratio [HR] vs all other endotypes 1·86 [95% CI 1·21-2·86]; p=0·0045), compared with 23 (22%) of 105 people with a Mars2 endotype (HR 0·64 [0·40-1·04]; p=0·061), 16 (23%) of 71 people with a Mars3 endotype (HR 0·71 [0·41-1·22]; p=0·19), and 13 (33%) of 40 patients with a Mars4 endotype (HR 1·13 [0·63-2·04]; p=0·69). Analysis of the net reclassification improvement using a combined clinical and endotype model significantly improved risk prediction to 0·33 (0·09-0·58; p=0·008). A 140-gene expression signature reliably stratified patients with sepsis to the four endotypes in both the first and second validation cohorts. Only Mars1 was consistently significantly associated with 28-day mortality across the cohorts. To facilitate possible clinical use, a biomarker was derived for each endotype; BPGM and TAP2 reliably identified patients with a Mars1 endotype. INTERPRETATION: This study provides a method for the molecular classification of patients with sepsis to four different endotypes upon ICU admission. Detection of sepsis endotypes might assist in providing personalised patient management and in selection for trials. FUNDING: Center for Translational Molecular Medicine, Netherlands.
引用
- Scicluna BP, van Vught LA, Zwinderman AH, et al. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. Lancet Respir Med. 2017. PMID: 28864056. doi:10.1016/S2213-2600(17)30294-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。